Towards Healthcare
Liver Cancer Drugs Market Size Soars 14.2% CAGR by 2034

Liver Cancer Drugs Market Size Innovations, Trends and Opportunities

According to market projections, the global liver cancer drugs market, valued at USD 3.05 billion in 2024, is anticipated to reach USD 11.5 billion by 2034, growing at a CAGR of 14.2% over the next decade. Liver cancer drugs are medicines used to treat liver cancer by stopping cancer cell growth, shrinking tumors, or boosting the immune system to fight the disease. They include targeted therapies, immunotherapies, chemotherapy, and newer treatments that improve survival and quality of life.

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global Liver Cancer Drugs Market Assessment

  • Overview
  • Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America Liver Cancer Drugs Market Assessment

  • Overview
  • North America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • North America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Europe Liver Cancer Drugs Market Assessment

  • Overview
  • Europe Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Europe Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Asia Pacific Liver Cancer Drugs Market Assessment

  • Overview
  • Asia Pacific Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Asia Pacific Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Middle East and Africa Liver Cancer Drugs Market Assessment

  • Overview
  • Middle East and Africa Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • Middle East and Africa Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

South America Liver Cancer Drugs Market Assessment

  • Overview
  • South America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
    • Targeted Therapy 
      • Bevacizumab
      • Cabozantinib
      • Lenvatinib
      • Ramucirumab
      • Regorafenib
      • Sorafenib
      • Other Targeted Therapies
    • Immunotherapy 
      • Atezolizumab with Bevacizumab
      • Nivolumab with Ipilimumab
      • Pembrolizumab
      • Durvalumab with Tremelimumab
      • Other Immunotherapies
    • Chemotherapy 
      • Gemcitabine
      • Oxaliplatin
      • Cisplatin
      • Doxorubicin
      • 5-fluorouracil
      • Capecitabine
      • Mitoxantrone
      • Other Chemotherapies
  • South America Liver Cancer Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy

Company Profiles

  • Bayer AG
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Bristol-Myers Squibb Company
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Merck KGaA
  • Pfizer Inc.
  • Eisai Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.

Conclusion & Recommendations

  • Insight Code: 5146
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: May 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology, and healthcare services.

She began her research career at Precedence Research, where she contributed to a wide range of healthcare industry studies, helping build a strong foundation in market intelligence and strategic research. Currently, Deepa plays a critical role at Towards Healthcare, while also extending her research capabilities across Statifacts, supporting cross-industry intelligence initiatives with a focus on healthcare.

Her ability to distill complexity into clarity has made her a trusted contributor to both internal teams and external clients across the healthcare value chain. By combining professionalism with an evolving depth in healthcare research, Deepa consistently adds value to projects that demand critical thinking, market precision, and industry-specific knowledge. Her contributions help organizations navigate the complexities of regulated markets and make data-backed growth decisions.

FAQ's

In the upcoming years, the liver cancer drugs market is anticipated to rise significantly due to factors like increased research and development, an expanding patient base, and an emphasis on personalized therapy.

Some major obstacles to the approval of new drugs are as follows: Safety-related issues: Carefully assessing the possible adverse effects of novel medications is necessary. Authorities that oversee cost-effectiveness consider the potential advantages of a treatment about its cost.

Despite recent progress, liver cancer treatment still needs a great deal of improvement. These unfulfilled needs include: improved medications for advanced hepatic carcinoma decreased adverse effects and increased efficacy, early identification, and diagnosis.

Global Cancer Observatory, American Liver Foundation, World Health Organization, National Institute of Health.